AllAnalyst Report
Morningstar•October 05, 2020
Morningstar•October 05, 2020Bristol-Myers Squibb Company: Bristol Announces MyoKardia Acquisition at Fair Price, Shoring Up an Already Deep Pipeline
Summary
Bristol-Myers Squibb discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpha
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeActions
Download Full ReportRelated Reports
- Analyst Report: Biogen Inc.Apr 24, 2024 •
BIIB
- Analyst Report: Abbott LaboratoriesApr 23, 2024 •
ABT
- Market Update: ABT, ERIC, IVZApr 23, 2024 •
ABT, ERIC, IVZ
- Analyst Report: Novartis AGApr 23, 2024 •
NVS
- The Argus Innovation Model PortfolioApr 23, 2024 •
GOOGL, AMAT, AAPL, ANET, CVX, ADI, AXON, URI, COST, V, LLY, SPGI, PANW, META, NVDA, SYK, BSX, ORCL, CBOE, PWR, MCK, NOW, ADBE, LYFT, SCHW, MCHP, ISRG, AMZN, ODFL, CRM
Analyst Profile
Damien Conover
Sector DirectorDamien Conover, CFA, is director of healthcare equity research for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He is also director of equity strategy, responsible for helping to shape, package, and surface research based on Morningstar's investment philosophy by working closely with the firm's North American sector strategists and directors.Before joining Morningstar in 2007, Conover was an equity research analyst covering the healthcare sector for Raymond James, Bank of Montreal, and Tucker Anthony.Conover holds bachelor's and master's degrees in finance from the University of Wisconsin and was a member of its Applied Security Analysis Program. He also holds the Chartered Financial Analyst® designation.